secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0000950170-25-036820
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking signs $150M manufacturing deal with CordenPharma for VK2735 supply
-------------------------------------------------------------------------

- Viking prepays $150M over 2025-2028 for dedicated API and fill/finish capacity for obesity drug VK2735.
- CordenPharma commits to multi-ton annual API supply; dedicated lines for 100M autoinjectors and 100M vial/syringe units.
- Annual oral tablet capacity exceeds 1 billion units; capacities are expandable at Viking's option.
- Phase 3 subcutaneous VK2735 trial planned to start Q2 2025; oral Phase 2 VENTURE trial ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000095017025036820/0000950170-25-036820-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000095017025036820/vktx-20250310.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-036820

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer